Due to many factors, such as point mutations in the ligand-binding domain of the androgen receptor(AR) and expression of splice variants, the existing treatment methods for prostate cancer have been successively ineffective. Therefore, new strategies for prostate cancer treatment are urgently needed. In recent years, significant progress has been made in targeted protein degradation technology. For example, AR degraders, which are expected to solve the problem of drug resistance in clinical prostate cancer patients, can block the androgen receptor signaling pathway by promoting AR degradation. This review focuses on the proteolysis targeting chimeras(PROTAC) technology and small molecule degraders targeting AR, and summarizes the research progress in this field from the mechanism of action and representative compounds, respectively. Compared with the inherent druggability defects of PROTAC molecules, small molecule AR degraders have more advantages and are now becoming the leading research direction for the treatment of prostate cancer.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |